CFI-402411,pembrolizumab
treadwell therapeutics,merck
['treadwell ']
treadwell therapeutics is pleased to announce a presentation for cfi-402411, an oral, first-in-class inhibitor hpk1, at the 37th society for immunotherapy of cancer (sitc) annual meeting from nov. 8-12, 2022 in boston, ma. #sitc22 #sitc2022 